Scary to think we’ve been so diluted now that a 0.4c per share...

Scary to think we’ve been so diluted now that a 0.4c per share offer could be enough to buy all of the medtech investment that has gone into this to date. This would represent a sufficient premium to the current rock bottom share price that I can’t see how the BoD could not recommend accepting it. It would also deliver Mary-Beth about $330K too from today’s transition agreement (excluding any shares she might own), which would be about the equivalent of one year of her annual salary up to this point.

That said, it could still represent a buying opportunity for us up to that theoretical price. If they announced this sort of buyout price I’d be front and centre to line-wipe the 0.2c and 0.3c sellers. All just imo of course.